PalmeaPharma SA, a Swiss-based biotechnology company, is developing high-value inhibitors targeting enzymes playing a critical role in protein stability, intracellular trafficking, protein interactions and membrane association.

Our goal is to address unmet medical needs in the fields of infectious diseases and inflammatory disorders, in particular for biodefense applications.

PalmeaPharma develops innovative and highly effective medical countermeasures against anthrax attacks.

A family of host enzymes playing a key role in anthrax intoxication has been identified and discovery-stage proprietary small molecule inhibitors are currently being developed. Tested in a robust set of in vitro assays, prototype inhibitors have shown unprecedented efficacy to prevent cell intoxication.

PalmeaPharma aims at providing a rapid, safe, and high-quality therapeutic solution for stockpiling by national and international agencies.